Citigroup assumed coverage on shares of Repligen (NASDAQ:RGEN) in a research report issued on Friday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $45.00 price target on the biotechnology company’s stock. Citigroup’s target price would indicate a potential upside of 26.55% from the company’s previous close.

Several other research analysts have also commented on RGEN. Zacks Investment Research upgraded Repligen from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a research report on Saturday, August 12th. J P Morgan Chase & Co began coverage on Repligen in a research report on Tuesday. They issued an “overweight” rating and a $42.00 price target for the company. TheStreet upgraded Repligen from a “c+” rating to a “b-” rating in a research report on Friday, August 11th. Stephens reiterated an “overweight” rating and issued a $50.00 price target on shares of Repligen in a research report on Tuesday, September 26th. Finally, First Analysis upgraded Repligen from an “equal weight” rating to an “overweight” rating and set a $47.00 price target for the company in a research report on Monday, October 2nd. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Repligen currently has a consensus rating of “Buy” and an average price target of $44.38.

Repligen (RGEN) traded up $0.98 on Friday, reaching $35.56. The company had a trading volume of 265,632 shares, compared to its average volume of 324,849. The stock has a market capitalization of $1,513.46, a price-to-earnings ratio of 59.90, a P/E/G ratio of 2.27 and a beta of 1.04. Repligen has a 12 month low of $28.48 and a 12 month high of $46.81.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, November 9th. The biotechnology company reported $0.15 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.11 by $0.04. The company had revenue of $36.58 million during the quarter, compared to analyst estimates of $35.69 million. Repligen had a return on equity of 7.57% and a net margin of 16.93%. The firm’s revenue was up 48.2% on a year-over-year basis. During the same quarter last year, the business posted $0.08 earnings per share. equities research analysts expect that Repligen will post 0.61 EPS for the current year.

Several large investors have recently made changes to their positions in the business. BlackRock Inc. boosted its position in shares of Repligen by 3.7% during the second quarter. BlackRock Inc. now owns 4,834,853 shares of the biotechnology company’s stock valued at $200,355,000 after buying an additional 170,551 shares during the period. TimesSquare Capital Management LLC boosted its position in shares of Repligen by 19.8% during the second quarter. TimesSquare Capital Management LLC now owns 2,361,270 shares of the biotechnology company’s stock valued at $97,851,000 after buying an additional 390,545 shares during the period. Vanguard Group Inc. boosted its position in shares of Repligen by 9.7% during the second quarter. Vanguard Group Inc. now owns 1,984,393 shares of the biotechnology company’s stock valued at $82,233,000 after buying an additional 175,191 shares during the period. Conestoga Capital Advisors LLC boosted its position in shares of Repligen by 12.5% during the third quarter. Conestoga Capital Advisors LLC now owns 1,453,232 shares of the biotechnology company’s stock valued at $55,688,000 after buying an additional 161,427 shares during the period. Finally, FMR LLC boosted its position in shares of Repligen by 6.2% during the second quarter. FMR LLC now owns 1,334,090 shares of the biotechnology company’s stock valued at $55,285,000 after buying an additional 78,060 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Repligen (RGEN) Coverage Initiated by Analysts at Citigroup” was reported by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/12/08/repligen-rgen-coverage-initiated-by-analysts-at-citigroup.html.

About Repligen

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Co. and related companies with MarketBeat.com's FREE daily email newsletter.